Acute myocardial infarction, stroke, and MACE in COPD patients treated with aclidinium and other inhaled bronchodilators. Saigi-Morgui N, Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud SZ, McMahon P, Perez-Gutthann S, Rivero-Ferrer E.
As part of a postauthorization safety study sponsored by AstraZeneca, we evaluated cardiovascular safety endpoints related to the use of aclidinium.
The study evaluated the risk of acute myocardial infarction, stroke, and other major adverse cardiac events in new users of aclidinium, aclidinium/formoterol, and other inhaled COPD medications compared with new users of long-acting beta agonists. This cohort study included patients with COPD aged 40 years or older initiating the study medications in the UK Clinical Practice Research Datalink between 2012 and 2019. Results showed that current use of aclidinium and other study medications was not associated with a clinically meaningful risk of any of the study outcomes.